Compared to monotherapy, combined administration of PARPi and EGFR inhibitors has shown better antitumor effects in ovarian cancer A2780 xenografts, mainly through the activation of the ERK (MAPK) and JNK and inhibition of the AKT/mTOR/(p70S6K) pathways [111]. Here, RPS6KB1 is linked to ovarian carcinoma.